Performance of BRCA1/ 2 mutation prediction models in male breast cancer patients-Reference-Cited by-同舟云学术

Performance of BRCA1/ 2 mutation prediction models in male breast cancer patients

Published:2017-09-25 Issue:1 Volume:93 Page:52-59
ISSN:0009-9163
Container-title:Clinical Genetics
language:en
Short-container-title:Clin Genet

Author:

Moghadasi S.¹^ORCID,Grundeken V.¹,Janssen L.A.M.¹,Dijkstra N.H.²,Rodríguez-Girondo M.³,van Zelst-Stams W.A.G.⁴,Oosterwijk J.C.⁵,Ausems M.G.E.M.⁶,Oldenburg R.A.⁷,Adank M.A.⁸,Blom E.W.⁹,Ruijs M.W.G.¹⁰,van Os T.A.M.¹¹,van Deurzen C.H.M.¹²,Martens J.W.M.¹³,Schroder C.P.¹⁴,Wijnen J.T.¹¹⁵,Vreeswijk M.P.G.¹⁵,van Asperen C.J.¹

Affiliation:

1. Department of Clinical Genetics; Leiden University Medical Centre; Leiden the Netherlands

2. Dutch Breast Cancer Research Group; Amsterdam the Netherlands

3. Department of Medical Statistics and Bioinformatics; Leiden University Medical Centre; Leiden the Netherlands

4. Department of Human Genetics; Radboud University Medical Centre; Nijmegen the Netherlands

5. Department of Genetics; University of Groningen, University Medical Centre Groningen; Groningen the Netherlands

6. Department of Genetics; University Medical Centre; Utrecht the Netherlands

7. Department of Clinical Genetics; Erasmus Medical Centre; Rotterdam the Netherlands

8. Department of Clinical Genetics; VU University Medical Centre; Amsterdam the Netherlands

9. Department Clinical Genetics; Maastricht University Medical Centre; Maastricht the Netherlands

10. Department of Clinical Genetics; the Netherlands Cancer Institute; Amsterdam the Netherlands

11. Department of Clinical Genetics; Academic Medical Centre; Amsterdam the Netherlands

12. Department of Pathology; Erasmus Medical Centre; Rotterdam the Netherlands

13. Department of Medical Oncology; Erasmus Medical Centre; Rotterdam the Netherlands

14. Department of Medical Oncology; University of Groningen, University Medical Centre Groningen; Groningen the Netherlands

15. Department of Human Genetics; Leiden University Medical Centre; Leiden the Netherlands

Funder

Netherlands Organization for Scientific Research (NWO)

Leiden University Medical Centre

Leids Universiteits Fonds

Simonsfonds

Publisher

Wiley

Subject

Genetics (clinical),Genetics

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/cge.13065/fullpdf

Reference43 articles.

1. Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer;Zhang;Int J Cancer,2015

2. PARP inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies;Lee;Ann Oncol,2014

3. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers;Tai;J Natl Cancer Inst,2007

4. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary;Asperen;J Med Genet,2005

5. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions;Antoniou;Br J Cancer,2008

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Validation of the BOADICEA model for predicting the likelihood of carrying pathogenic variants in eight breast and ovarian cancer susceptibility genes;Scientific Reports;2023-05-26

2. Male Breast Cancer: From Molecular Genetics to Clinical Management;Cancers;2022-04-15

3. Implications of BRCA1, BRCA2 Gene in Overall Development and Prognosis of Breast Cancer;Breast Cancer: From Bench to Personalized Medicine;2022

4. A Pragmatic Testing-Eligibility Framework for Population Mutation Screening: The Example of BRCA1/2;Cancer Epidemiology Biomarkers & Prevention;2019-01-28

5. Unmet needs of men with breast cancer;European Journal of Surgical Oncology;2018-08